Olr704 inhibitors represent a specialized category of chemical compounds that interact specifically with the Olr704 receptor, a member of the olfactory receptor family. These receptors are G protein-coupled receptors (GPCRs) primarily involved in the detection of odorants, playing a critical role in the olfactory system. Olr704, like other olfactory receptors, spans the cellular membrane and undergoes conformational changes upon binding with specific ligands. The inhibition of Olr704 is a fascinating area of study because it provides insights into the molecular mechanisms underlying olfaction, a complex sensory process. Researchers are particularly interested in understanding how these inhibitors bind to the receptor, the structural features that facilitate their selective interaction, and the resultant biochemical cascades that are modulated upon inhibition.
Investigating Olr704 inhibitors involves a multidisciplinary approach that encompasses organic chemistry, structural biology, and biophysics. Chemists synthesize a variety of inhibitor molecules, often employing structure-activity relationship (SAR) studies to refine their efficacy and selectivity. Structural biologists utilize techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy to elucidate the three-dimensional structures of the receptor-inhibitor complexes. Furthermore, computational modeling and molecular dynamics simulations are employed to predict binding affinities and identify key interaction sites. These studies contribute significantly to the broader understanding of GPCR functionality and olfactory signal transduction. By dissecting the interactions at the atomic level, scientists can map out the intricate network of forces that govern inhibitor binding and receptor activity, thus advancing the fundamental knowledge of sensory perception and molecular signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Modulates immune response and inhibits angiogenesis, potentially affecting proteins in these pathways. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Inhibits EGFR tyrosine kinase, potentially affecting proteins in the EGFR signaling pathway. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Dihydrofolate reductase inhibitor, potentially disrupting DNA synthesis and affecting cell replication proteins. | ||||||
Pomalidomide | 19171-19-8 | sc-364593 sc-364593A sc-364593B sc-364593C sc-364593D sc-364593E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $100.00 $143.00 $312.00 $468.00 $1248.00 $1997.00 | 1 | |
Immunomodulatory drug, potentially influencing proteins in immune response and angiogenesis. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, potentially affecting protein degradation and cell cycle regulation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases, potentially disrupting proteins in cell signaling and growth pathways. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Inhibits cyclin-dependent kinases 4 and 6, potentially affecting cell cycle-related proteins. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Proteasome inhibitor, potentially impacting protein degradation and cell cycle regulation. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Cyclin-dependent kinase 4/6 inhibitor, potentially affecting proteins involved in cell cycle regulation. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Inhibits MET, VEGFR, and RET, potentially disrupting multiple signaling pathways. | ||||||